Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q6PCB5
UPID:
RSBNL_HUMAN
Alternative names:
Round spermatid basic protein 1-like protein
Alternative UPACC:
Q6PCB5; C9K0P1; Q6ZS58; Q6ZVI9; Q86X48
Background:
Lysine-specific demethylase RSBN1L, also known as Round spermatid basic protein 1-like protein, plays a crucial role in epigenetic regulation by specifically demethylating methylated lysine residues of proteins. This process is vital for the modulation of gene expression, impacting cellular differentiation, and development.
Therapeutic significance:
Understanding the role of Lysine-specific demethylase RSBN1L could open doors to potential therapeutic strategies. Its unique function in the regulation of gene expression through demethylation makes it a promising target for drug discovery, aiming to correct epigenetic malfunctions associated with various diseases.